ABL1 Q252R

CI-VAR-00003528Explore in graph →NP_005148.2:p.Gln252ArgNM_005157.5:c.755A>GCIViC 1600

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive1
BCR::ABL1 Fusion AND ABL1 Q252R	Dasatinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID4693 In an in vitro study, a Ba/F3 cell line stably expressing the Q252R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have increased sensitivity to dasatinib treatment, as comp… (full text at CIViC) PMID 15256671 · Shah et al., 2004 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.